Biohaven pauses new U.S. enrollment after FDA partial clinical hold
Biohaven paused new U.S. patient enrollment in its BHV-7000 program after an FDA partial clinical hold. Dosing continues for already randomized patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.